Redcare Pharmacy's Leadership Reshuffle Meets a Critical Policy Crossroads

Redcare Pharmacy posts strong Q1 2026 revenue growth but stock plunges. Shareholders to vote on new leadership as max investment year pressures margins.

Redcare Pharmacy's annual general meeting on April 15 is set to formalize a sweeping leadership overhaul, a strategic pivot arriving at a moment of stark operational contrast. While the online pharmacy giant posted robust first-quarter growth, its stock has been decimated, losing roughly 40% since the start of the year and over 65% on a twelve-month basis. The gathering of shareholders will vote on a new financial chief and a refreshed supervisory board, aiming to steer the company through intense competitive pressure and a peak investment cycle.

The operational performance tells a story of strength, particularly in its core prescription business. For Q1 2026, group revenue climbed 18.3% to €848 million, surpassing analyst expectations of €837 million. The Rx segment was the standout, with global sales of prescription medicines surging 35% to €315 million. In its home German market, that growth accelerated to 55%, reaching €168 million. Even the over-the-counter (OTC) division showed renewed vigor, expanding by 9.7% after a prior period of slower growth.

This solid footing, however, is being overshadowed by significant strategic headwinds and costs. The company has declared 2026 a year of maximum investment, centered on a new logistics hub in Pilsen, Czech Republic, which will boost annual capacity by 15 million parcels. This heavy capital expenditure is pressuring profitability, leading management to revise its medium-term margin target down from over 8% to more than 5%. The stock, trading at €42.08, reflects this strain, sitting nearly 39% below its 200-day moving average and languishing near the bottom of the MDAX index.

Competitive threats are adding to investor anxiety. The December 2025 launch of dm's "dm-med" platform and similar plans from Rossmann have rattled the market, primarily over fears of erosion in the OTC segment. A key defensive moat remains Redcare's commanding 67% market share in German online prescription sales, a position reinforced by Rossmann's confirmation that it will not offer prescription medications.

Amid these challenges, a potential tailwind is emerging from Berlin. A government-appointed expert commission has recommended raising statutory co-payments for prescription drugs by 50%. If enacted, patients would pay between €7.50 and €15 per prescription, up from the current €5 to €10 range. Health Minister Nina Warken has pledged to advance corresponding legislation swiftly. Analysts like Felix Dennl of Bankhaus Metzler view this as a structural advantage for mail-order pharmacies, arguing that higher out-of-pocket costs will push price-sensitive customers from brick-and-mortar pharmacies toward cheaper online alternatives.

The leadership team tasked with navigating this complex landscape will see a major refresh. Hendrik Krampe, the designated new CFO bringing two decades of e-commerce experience from Amazon and eBay, will be formally appointed. His expertise in scaling platforms is seen as crucial for Redcare's next phase. He will be joined by three new candidates—Anja Hendel, Max Müller, and Peter Schmid von Linstow—entering the supervisory board, replacing three long-standing members.

Management has reaffirmed its full-year 2026 targets, which include revenue growth of 13-15%, German Rx sales exceeding €670 million, and an adjusted EBITDA margin of at least 2.5%. The investment ratio is expected to fall below 2% of sales after 2026, with 2025 and 2026 marked as peak years.

The first major test for the newly configured team comes on May 6 with the release of the complete quarterly report. The market will scrutinize whether the powerful prescription momentum can sufficiently offset the investment drag and begin to bridge the glaring gap between the company's operational health and its battered valuation.